IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Retension and TRex Bio File for US IPOs

Drug developers Retension Pharmaceuticals and TRex Bio filed paperwork for US initial public offerings on Friday. The listings add breadth to the active fall biotech IPO pipeline supported by major acquisitions.

Xurve View
Insights:
U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration

Retension Pharmaceuticals and TRex Bio filed for United States initial public offerings on Friday morning, adding breadth to the autumn IPO window. The dual filings follow a wave of biotech acquisitions by large drugmakers. Biotech listings have proven resilient against broader market pressures.
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.